Ligand Pharmaceuticals (LGND)
Builds biopharmaceutical royalty portfolios and licenses Captisol and NITRICIL drug technologies.
$298.08
vs last close−0.42 (−0.14%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
$2.28
Revenue estimate
$78.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.64$1.33$1.60$3.09$2.02$1.63$2.37Pending
Estimate$1.37$1.21$1.42$1.97$1.46$1.84$2.01$2.28
Surprise−219.7%+9.9%+12.7%+56.9%+38.4%−11.4%+17.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$42.8M$45.3M$47.6M$115.5M$59.7M$51.7M$63.7MPending
Estimate$39.0M$38.7M$43.9M$58.7M$55.6M$59.1M$61.3M$78.1M
Surprise+9.7%+17.1%+8.6%+96.5%+7.3%−12.5%+3.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $3.36 | — | — |
| Sep 2027 | $2.98 | — | — |
| Jun 2027 | $2.70 | — | — |
| Mar 2027 | $2.30 | — | — |
| Dec 2026 | $3.01 | — | — |
| Nov 2026 | $2.28 | — | — |
| Aug 2026 | $2.01 | $2.37 | +17.9% |
| May 2026 | $1.84 | $1.63 | −11.4% |
| Feb 2026 | $1.46 | $2.02 | +38.4% |
| Nov 2025 | $1.97 | $3.09 | +56.9% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $3.36 | — | — | $100.1M | — | — | — |
| Sep 2027 | $2.98 | — | — | $90.7M | — | — | — |
| Jun 2027 | $2.70 | — | — | $85.7M | — | — | — |
| Mar 2027 | $2.30 | — | — | $76.1M | — | — | — |
| Dec 2026 | $3.01 | — | — | $97.4M | — | — | — |
| Nov 5, 2026 | $2.28 | — | — | $78.1M | — | — | — |
| Aug 6, 2026 | $2.01 | $2.37 | +17.9% | $61.3M | $63.7M | +3.9% | −0.8% |
| May 14, 2026 | $1.84 | $1.63 | −11.4% | $59.1M | $51.7M | −12.5% | −1.0% |
| Feb 26, 2026 | $1.46 | $2.02 | +38.4% | $55.6M | $59.7M | +7.3% | +2.5% |
| Nov 6, 2025 | $1.97 | $3.09 | +56.9% | $58.7M | $115.5M | +96.5% | +9.4% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 7, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 22, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 17, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Jul 29, 2021 | |||||||
| May 3, 2021 | |||||||
| Feb 3, 2021 | |||||||
| Oct 30, 2020 | |||||||
| Aug 3, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Jul 30, 2019 | |||||||
| May 2, 2019 | |||||||
| Feb 7, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 21, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 23, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 4, 2016 | |||||||
| Feb 10, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 4, 2015 |